Dong-A ST, MetaVia Confirm Blood Sugar Benefits of Obesity Candidate in Preclinical Study
- Input
- 2026-11-17 15:02:31
- Updated
- 2026-11-17 15:02:31

Dong-A ST and MetaVia said on the 17th that they presented results from a preclinical comparative study of DA-1726 and retatrutide at ObesityWeek 2026, held by The Obesity Society in Washington, D.C., on the 14th.
DA-1726 is a dual agonist that acts on both GLP-1 and glucagon receptors. It is being developed to promote weight loss and blood sugar control by suppressing appetite while increasing energy expenditure. Retatrutide is an obesity treatment candidate being developed by Eli Lilly and is a triple agonist that acts on GLP-1, GIP and glucagon receptors.
The researchers administered the two candidate drugs to diet-induced obese mice twice a week for about three weeks and compared body weight, blood sugar, food intake and blood lipid levels, among other measures.
The two drugs had similar effects on weight loss. The weight reduction rates in the DA-1726 groups were 34.2% at the low dose and 41.7% at the high dose, while the corresponding rates in the retatrutide groups were 33.7% and 43.6%. By contrast, blood sugar reduction was greater with DA-1726, at 43.0% for the low dose and 39.2% for the high dose, than with retatrutide, at 21.5% and 32.5%, respectively.
Retatrutide was more effective at reducing food intake. Intake fell by 19.6% and 31.2% in the DA-1726 groups at the low and high doses, respectively, compared with 36.7% and 41.4% in the retatrutide groups. Thus, the drugs achieved similar weight loss even though DA-1726 had a relatively smaller effect on suppressing food intake.
Improvements in lipid metabolism were also observed. Total cholesterol fell by up to 70.9% and LDL cholesterol by up to 89.9% in the DA-1726 groups. The corresponding reductions in the retatrutide groups were up to 69.0% and 88.1%, respectively, showing similar results.
The researchers also noted that DA-1726 increased gene expression and protein levels of FGF21, which is involved in metabolic regulation in the liver. Gene expression also increased for genes involved in heat production in brown fat and the browning of white fat. This suggests that DA-1726 may affect weight loss not only by suppressing appetite but also through pathways that increase energy expenditure.
Based on these preclinical results and the reductions in liver fat and body weight observed in recent clinical trials, MetaVia plans to begin Phase 2 trials in the second half of 2027 in patients with metabolic dysfunction-associated steatotic liver disease with alcohol use (MetALD) and alcohol-related liver disease (ALD).
[email protected] Jung Sang-hee Reporter